Benlysta Autoinjector

Benlysta Autoinjector Uses, Dosage, Side Effects, Food Interaction and all others data.

Benlysta Autoinjector is an intravenous immunosupressant for the adjunctive treatment of systemic lupus erythematosus (SLE). More specifically, it is a fully human recombinant IgG1λ monoclonal antibody produced from a recombinant NS0 cell line stably transfected with the belimumab heavy chain and light chain genes. It is the first biological treatment approved for the indication of SLE. Concomitant use with live or inactivated vaccines must be avoided. Benlysta Autoinjector was FDA approved on March 9, 2011. Benlysta Autoinjector consists of 2 heavy chains, and 2 light chains of the lambda subclass. Each heavy chain contains 452 amino acid residues and each light chain contains 214 amino acid residues. There are 3 post-translational modifications: a conserved N-linked glycosylation on the CH2 domain at Asn 303 of the heavy chain, the conversion of the N-terminal glutamine residue of the heavy chain into pyroglutamate, and loss of C-terminal lysine residue of the heavy chain.

By the 52nd week of treatment with belimumab, a reduction in CD19+, CD20+, naive and activated B cells, plasma cells, plasmacytoid cells, and SLE B-cell subset can be observed. Reductions in plasma cells and SLE B-cell subset can be seen by the eighth week and these levels were maintained to week 52. Benlysta Autoinjector also reduced levels of IgG and anti-dsDNA.

Benlysta Autoinjector
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Benlysta Autoinjector
Availability	Prescription only
Generic	Belimumab
Belimumab Other Names	Belimumab
Related Drugs	Benlysta, aspirin, prednisone, dexamethasone, triamcinolone, hydroxychloroquine, Plaquenil, Lupkynis, voclosporin
Weight	120mg, 400mg, 200mg/ml
Type	Intravenous powder for injection, subcutaneous solution
Formula	C₆₃₅₈H₉₉₀₄N₁₇₂₈O₂₀₁₀S₄₄
Weight	147000.0 Da
Groups	Approved
Therapeutic Class
Manufacturer
Available Country	United States
Last Updated:	September 19, 2023 at 7:00 am

Uses

Benlysta Autoinjector is a B-lymphocyte stimulator (BLyS)-specific inhibitor that indirectly inhibits B cell survival, and is used to treat patients with autoantibody positive, active systemic lupus erythematosus.

Adjunct treatment for auto-antibody-positive active systemic lupus erythematosus (SLE). The intravenous injectable form is the only FDA approved treatment for pediatric patients with SLE.

Benlysta Autoinjector is also used to associated treatment for these conditions: Active autoantibody-positive Systemic lupus erythematosus

How Benlysta Autoinjector works

Benlysta Autoinjector selectively binds to soluble human B lymphocyte stimulator protein (BLyS) so that BLyS is unable to bind to receptors on B lymphocytes. The binding of BLyS to its receptor is essential for the survival of B lymphocytes. Consequently, belimumab reduces B-cell mediated immunity and the autoimmune response.

Toxicity

The most commonly-reported adverse reactions, occurring in ≥5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis. The most common serious adverse reactions were serious infections.